2024 / 06

Next Paper
DOI: 10.24075/brsmu.2024.052

ORIGINAL RESEARCH

T-cell receptor chain centricity in the primarily activated effectors and re-stimulated memory cells

Kalinina AA1, Kubekina MV2, Persiyantseva NA1, Bruter AV1,2, Khromykh LM1, Kazansky DB1
About authors

1 Blokhin National Medical Research Center of Oncology, Moscow, Russia

2 Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Institute of Gene Biology, Moscow, Russia

Correspondence should be addressed: Dmitry B. Kazansky
Kashirskoye Shosse, 24, bld. 15, Moscow, 115478, Russia; ur.xednay@1yksnazak

About paper

Funding: the study was supported by the RSF grant No. 22-15-00342 (2022–2024).

Acknowledgements: the authors would like to express their gratitude to O. Britanova (Institute of Bioorganic Chemistry RAS) and K. Lupyr (Skolkovo Institute of Science and Technology) for generation and bioinformatics analysis of the mouse TCR α-chain libraries.

Author contribution: Kalinina AA — study planning, literature review, experimental procedure, data analysis and interpretation, manuscript writing; Kubekina MV — cloning; Persiyantseva NA — transfection; Bruter AV — selection of oligonucleotides, cloning; Khromykh LM — study planning, literature review, data analysis and interpretation, manuscript editing; Kazansky DB — study planning, literature review, data analysis and interpretation, manuscript editing.

Compliance with ethical standards: the study was approved by the Ethics Committee of the Blokhin National Medical Research Center of Oncology (protocol No. 3P-10.06.2022 dated 10 June 2022), it was conducted in strict compliance with the provisions of the Directive 2010/63/EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientific purposes.

Received: 2024-10-09 Accepted: 2024-10-30 Published online: 2024-11-30
|
  1. Kalinina AA, Khromykh LM, Kazansky DB. T Cell Receptor Chain Centricity: The Phenomenon and Potential Applications in Cancer Immunotherapy. Int J Mol Sci. 2023; 24: 15211.
  2. Ochi T, Nakatsugawa M, Chamoto K, Tanaka S, Yamashita Y, Guo T, et al. Optimization of T-cell Reactivity by Exploiting TCR Chain Centricity for the Purpose of Safe and Effective Antitumor TCR Gene Therapy. Cancer Immunol Res. 2015; 3: 1070–81.
  3. Nakatsugawa M, Yamashita Y, Ochi T, Tanaka S, Chamoto K, Guo T, et al. Specific roles of each TCR hemichain in generating functional chain-centric TCR. J Immunol. 2015; 194: 3487–500.
  4. Kalinina AA, Nesterenko LN, Bruter AV, Balunets DV, Chudakov DM, Izraelson M, et al. Adoptive Immunotherapy Based on ChainCentric TCRs in Treatment of Infectious Diseases. iScience. 2020; 23 (12): 101854.
  5. Brändle D, Brduscha-Riem K, Hayday AC, Owen MJ, Hengartner H, Pircher H. T cell development and repertoire of mice expressing a single T cell receptor alpha chain. Eur J Immunol. 1995; 25: 2650–5.
  6. Mori L, Loetscher H, Kakimoto K, Bluethmann H, Steinmetz M. Expression of a transgenic T cell receptor beta chain enhances collagen-induced arthritis. J Exp Med. 1992; 176: 381–88.
  7. Zamkova MA, Kalinina AA, Silaeva YY, Persiyantseva NA, Bruter AV, Deikin AV, et al. Dominant role of the α-chain in rejection of tumor cells bearing a specific alloantigen inTCR transgenic mice and in in vitro experiments. Oncotarget. 2019; 10: 4808–21.
  8. Grinenko TS, Pobezinskaya EL, Pobezinskii LA, Baturina IA, Zvezdova ES, Kazanskii DB. Suppression of primary allogenic response by CD8+ memory cells. Bull Exp Biol Med. 2005; 140 (5): 545–9.
  9. Kalinina AА, Persiyantseva NА, Britanova OV, Lupyr K, Shagina I, Khromykh LM et al. Unique features of the TCR repertoire of reactivated memory T cells in the experimental mouse tumor model. Comput Struct Biotechnol J. 2023; 21: 3196–209.
  10. Kalinina A, Bruter A, Nesterenko L, Khromykh L, Kazansky D. Generation of TCRα-transduced T cells for adoptive transfer therapy of salmonellosis in mice. STAR Protoc. 2021; 2 (1): 100368.
  11. Kalinina AA, Khromykh LM, Kazansky DB, Deykin AV, Silaeva YY. Suppression of the immune response by syngeneic splenocytes adoptively transferred to sublethally irradiated mice. Acta Nat. 2021; 13 (1): 116–26.
  12. Dietrich PY, Le Gal FA, Dutoit V, Pittet MJ, Trautman L, Zippelius A, et al. Prevalent role of TCR alpha-chain in the selection of the preimmune repertoire specific for a human tumor-associated selfantigen. J Immunol. 2003; 170: 5103–9.
  13. Hebeisen M, Allard M, Gannon PO, Schmidt J, Speiser DE, Rufer N. Identifying individual T cell receptors of optimal avidity for tumor antigens. Front Immunol. 2015; 6: 582.
  14. Mondino A, Manzo T. To remember or to forget: the role of good and bad memories in adoptive T cell therapy for tumors. Front Immunol. 2020; 11: 1915.
  15. von Essen MR, Kongsbak M, Geisler C. Mechanisms behind functional avidity maturation in T cells. Clin Dev Immunol. 2012; 2012: 163453.
  16. Gilfillan CB, Hebeisen M, Rufer N, Speiser DE. Constant regulation for stable CD8 T-cell functional avidity and its possible implications for cancer immunotherapy. Eur J Immunol. 2021; 51 (6): 1348–60.
  17. Campillo-Davo D, Flumens D, Lion E. The quest for the best: how TCR affinity, avidity, and functional avidity affect TCR-engineered T-cell antitumor responses. Cells. 2020; 9(7): 1720.
  18. Kalinina A, Bruter A, Persiyantseva N, Silaeva Y, Zamkova M, Khromykh L et al. Safety evaluation of the mouse TCRα - transduced T cell product in preclinical models in vivo and in vitro. Biomed Pharmacother. 2022; 145: 112480.